Fenwick & West represented Model N, Inc. in its acquisition of LeapFrogRx. Model N creates applications and business intelligence solutions with comprehensive services to life sciences and high tech organizations and has more than $150 billion in annual revenues across 50 countries managed in its systems. LeapFrogRx is an emerging leader in business intelligence solutions for the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed.
The Fenwick transaction team included corporate attorney David Michaels, technology transaction attorney Lance Stern, executive compensation and employee benefits attorneys Scott Spector and Blake Martell, and tax attorneys Michael Solomon and Natalie Pardo De Zela.